Consensus statement on ischaemic stroke care in Hong Kong

Hong Kong Medical Journal

Volumn 10, Issue 2, 2004, Pages 124-129

  Ng, P W ^a   Huang, C Y ^b   Cheung, R T F ^c   Wong, K S ^d   Wong, C K ^e   Lam, J M K ^d  

^a UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^b Melbourne Plaza ^*  (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e NORTH DISTRICT HOSPITAL   (Hong Kong)

Author keywords

Brain ischemia; Cerebrovascular accident; Hong Kong; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NEUROPROTECTIVE AGENT; NIMODIPINE; PARACETAMOL; RECOMBINANT HUMAN INSULIN; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONSENSUS; DIABETES MELLITUS; FEVER; FIBRINOLYTIC THERAPY; GASTROINTESTINAL DISEASE; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH SERVICE; HONG KONG; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SUBARACHNOID HEMORRHAGE; UNITED STATES;

AGED; CEREBROVASCULAR ACCIDENT; COMBINED MODALITY THERAPY; CRITICAL ILLNESS; EMERGENCY TREATMENT; FEMALE; HONG KONG; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 1842763694     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. 2001 Hospital Authority Annual Report. Hong Kong: Hospital Authority; 2001.
2. Intercollegiate Working Party for Stroke. National clinical guidelines for stroke. London: Royal College of Physicians; 2000.
3. Scottish Intercollegiate Guidelines Network (SIGN). Management of patients with stroke I: Assessment, investigation, immediate management and secondary prevention. No 13. Edinburgh: SIGN; 1997.
4. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056-83.
5. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Stroke unit treatment. 10-year follow-up. Stroke 1999;30:1524-7.
6. Kalra L, Evens A, Perez I, Knapp M, Donaldson N, Swift CG. Alternative strategies for stroke care: a prospective randomised controlled trial. Lancet 2000;356:894-9.
7. Stroke Unit Trialists' Collaboration. Organized inpatient (stroke unit) care for stroke (Cochrane Review). In: the Cochrane Library, Issue 4, 2001. Oxford: Update software.
8. Blight A, Pereira AC, Brown MM. A single consultation cerebrovascular disease clinic is cost effective in the management of transient ischaemic attack and minor stroke. J R Coll Physicians Lond 2000;34:452-5.
9. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569-81.
10. CAST: randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997;349:1641-9.
11. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240-9.
12. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
13. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-8.
14. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.
15. Hommel M, for the FISS-bis Investigators Group. Fraxiparine in ischaemic stroke study (FISS bis). Cerebrovasc Dis 1998;8(Suppl 4): 19S.
16. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998;279:1265-72.
17. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32:2333-7.
18. Lees KR. Management of acute stroke. Lancet Neurol 2002;1:41-50.
19. Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999;30:1991-4.
20. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
22. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
23. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotic Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415-25.